Beta Bionics (NASDAQ: BBNX) CCO sells 5,329 shares to cover RSU taxes

Rhea-AI Filing Summary

Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported an open-market sale of 5,329 shares of Common Stock. The shares were sold at a weighted average price of $12.6071 per share to cover tax withholding obligations tied to the vesting of restricted stock units, according to the footnotes. After this transaction, Hopman directly holds 130,887 shares of Beta Bionics common stock, indicating that the sale represents a relatively small portion of his overall position and is primarily a tax-related event rather than a discretionary reduction in ownership.

Insights

Equity compensation and insider-transactions analyst

Sale is small, tax-driven, and routine for equity compensation.

The filing shows Chief Commercial Officer Mark Hopman sold 5,329 shares of Beta Bionics, Inc. common stock at a weighted average price of $12.6071 per share. Footnotes state this was to satisfy tax withholding from vesting restricted stock units.

Because the sale covers tax obligations on equity compensation, it is more mechanical than discretionary. After the sale, Hopman still directly owns 130,887 shares, so the transaction is a minor reduction relative to his total holdings.

Overall, this looks like a routine equity-compensation tax event rather than a signal of changing sentiment. The filing notes price ranges between $12.30 and $12.93, with detailed trade breakdowns available upon request.

Insider Trade Summary

Net Seller: 5,329 shares ($67,183)

Net Sell 1 txn

Insider Hopman Mark

Role Chief Commercial Officer

Sold 5,329 shs ($67K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,329	$12.6071	$67K

Holdings After Transaction: Common Stock — 130,887 shares (Direct, null)

Footnotes (1)

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 5,329 shares Weighted average sale price: $12.6071 per share Post-transaction holdings: 130,887 shares +1 more

4 metrics

Shares sold 5,329 shares Open-market sale on 2026-06-02

Weighted average sale price $12.6071 per share Tax-related sale to cover withholding

Post-transaction holdings 130,887 shares Common Stock held directly after sale

Sale price range $12.30–$12.93 per share Range of prices for reported sale

Key Terms

restricted stock units, weighted average sale price, open-market sale, Chief Commercial Officer

4 terms

restricted stock units financial

"tax withholding obligations associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $12.6071"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Chief Commercial Officer financial

"officer_title": "Chief Commercial Officer""

A chief commercial officer (CCO) is the senior executive responsible for a company’s revenue-generating activities, including sales, marketing, pricing, customer relationships and business development. Think of the CCO as the head coach who builds the game plan to win customers and grow sales; their effectiveness affects how fast a company earns money, enters new markets and sustains profits, making the role a key signal for investors about future revenue and competitive strength.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		S(1)		5,329	D	$12.6071(2)	130,887	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Beta Bionics (BBNX) report for Mark Hopman?

Beta Bionics reported that Chief Commercial Officer Mark Hopman sold 5,329 shares of common stock. The sale was conducted in the open market and is disclosed as part of his equity compensation activity, rather than as a large discretionary trade in the company’s shares.

Why did Mark Hopman sell Beta Bionics (BBNX) shares in this Form 4?

The filing states the shares were sold to cover tax withholding obligations from vesting restricted stock units. This means the transaction is largely a tax-related, mechanical event tied to equity compensation rather than a discretionary decision to significantly reduce his investment exposure.

How many Beta Bionics (BBNX) shares does Mark Hopman hold after the sale?

After selling 5,329 shares, Mark Hopman directly holds 130,887 shares of Beta Bionics common stock. This indicates that the reported sale represents only a small fraction of his total ownership, suggesting the transaction’s main purpose was satisfying tax obligations from RSU vesting.

At what price were the Beta Bionics (BBNX) shares sold in this insider transaction?

The filing reports a weighted average sale price of $12.6071 per share. It notes that the individual trades occurred within a price range from $12.30 to $12.93, and that detailed information on each specific sale price is available upon request from interested parties.

Is the Hopman Form 4 transaction for Beta Bionics (BBNX) a routine tax sale?

Yes. The footnotes explain the 5,329 shares were sold to cover tax withholding related to vesting restricted stock units. Such transactions are common for executives receiving equity compensation and generally reflect tax administration rather than a major shift in investment stance.